National Network of Depression Centers position statement: Insurance coverage for intravenous ketamine in treatment-resistant major depressive disorder
https://www.sciencedirect.com/science/article/abs/pii/S0165032723013691?via%3Dihub
- Mark J. Niciu, University of Iowa Health Care, Department of Psychiatry/Iowa Neuroscience Institute, Iowa City, IA 52242, USA
- Robert C. Meisner, McLean Hospital, Psychiatric Neurotherapeutics Program, 115 Mill St., Belmont, MA 02478, USA and Harvard Medical School, Department of Psychiatry, Boston, MA 02115, USA
- Brent R. Carr, University of Florida College of Medicine, Department of Psychiatry, Gainesville, FL 32610, USA
- Ali A. Farooqui, University of Louisville School of Medicine, Department of Psychiatry and Behavioral Sciences, Louisville, KY 40202, USA
- David Feifel, Kadima Neuropsychiatry Institute, La Jolla, CA 92037, USA and University of California San Diego School of Medicine, La Jolla, CA 92093, USA
- Adam Kaplin, Mira Pharmaceuticals, Baltimore, MD 21205, USA and the Johns Hopkins School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD 21205, USA
- Jeremy Kendrick, University of Utah School of Medicine, Department of Psychiatry, University Neuropsychiatric Institute, Salt Lake City, UT 84132, USA
- Christopher D. Schneck, University of Colorado Anschutz Medical Campus, Department of Psychiatry, Helen and Arthur E. Johnson Depression Center, Aurora, CO 80045, USA
- Jennifer L. Vande Voort, Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN 55905, USA
- Sagar V. Parikh, University of Michigan School of Medicine, Department of Psychiatry and Depression Center, Ann Arbor, MI 48109, USA
Received 18 July 2023, Revised 1 November 2023, Accepted 3 November 2023, Available online 6 November 2023, Version of Record 15 November 2023.